TC
CADX

TFS Capital’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

TFS Capital’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-253,559
Closed -$2.29M – 1841
2013
Q4 		$2.29M Buy
+253,559
New +$1.83M 0.11% 267
2013
Q3 		– Sell
-21,094
Closed -$144K – 1818
2013
Q2 		$144K Buy
+21,094
New +$147K 0.01% 1392

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TFS Capital's CADX Position: Q1 2014 in Review

TFS Capital sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 253,559 shares — an estimated $2.29M sold.

TFS Capital first reported a position in CADX in Q2 2013 and held it in 2 quarters. The position peaked at $2.29M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • TFS Capital reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • TFS Capital sold 253,559 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $2.29M.
  • TFS Capital first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 2 quarters.
  • TFS Capital's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $2.29M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on TFS Capital's 13F filing for Q1 2014, filed 5 May 2014.